Health Canada has approved Venus Medtech’s VenusP-Valve transcatheter pulmonic valve replacement (TPVR) system
The approval is supported by the results that demonstrated a 100% success rate in the 3yrs. follow-up data of the European study, 0 all-cause mortality and reintervention rates without moderate or severe pulmonary regurgitation, 96.87% of patients experienced mild or low paravalvular leakage & tricuspid regurgitation along with improved cardiac function
The VenusP-Valve System is developed to replace the pulmonary heart valve with an artificial valve for treating right ventricular outflow tract (RVOT) dysfunction and the dilated outflow tracts for restoring pulmonary valve function
Ref: Galderma | Image: Galderma
Related News:- Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
